Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Nitrosourea SCHEMBL27699579 | 0.77 | ADRA2A (0.41) | ADRA2APDE4AADRA1ACES2CES1 | |
| SCHEMBL3628742 | 0.75 | BCHE (0.49) | CES2CES1CNR2CNR1ALDH1A1 | |
| SCHEMBL21362892 | 0.75 | BCHE (0.49) | CES2CES1CNR2CNR1ALDH1A1 | |
| SCHEMBL103495 | 0.74 | L3MBTL1 (0.37) | ADRA2APDE4AADRA1AALDH1A1 | |
| SCHEMBL103334 | 0.74 | CES2 (0.42) | ADRA2APDE4AADRA1ACES2CES1 | |
| SCHEMBL483677 | 0.74 | BCHE (0.50) | CES2CES1CNR2CNR1HSD11B1 | |
| SCHEMBL13058298 | 0.73 | BCHE (0.50) | CNR2ALDH1A1 | |
| SCHEMBL701945 | 0.72 | ADRA2A (0.40) | ADRA2APDE4AADRA1AALDH1A1 | |
| SCHEMBL12424455 | 0.71 | BCHE (0.51) | CES2CES1CNR2CNR1NAAA | |
| SCHEMBL178740 | 0.71 | ADRA2A (0.53) | ADRA2APDE4AADRA1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8728442-B2 | Method of controlling the growth of microorganisms by a composition containing isolated or in vitro synthesized nitrosoamides | BAYER CROPSCIENCE LP (US) | 2014-05-20 | — | — | US | disclosed |
| US-8728442-B2 | Method of controlling the growth of microorganisms by a composition containing isolated or in vitro synthesized nitrosoamides | BAYER CROPSCIENCE LP (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120058058-A1 | COMPOUNDS DERIVED FROM MUSCODOR FUNGI | AGRAQUEST, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058058-A1 | COMPOUNDS DERIVED FROM MUSCODOR FUNGI | AGRAQUEST, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058058-A1 | COMPOUNDS DERIVED FROM MUSCODOR FUNGI | SPOUT1, ERG28, DDT | ADRA2A 4219/4885PDE4A 435/4885ADRA1A 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.